Business Wire

Fujirebio Acquires ADx Neurosciences and Confirms Its Intentions to Bring Better and Earlier Neurodegenerative Disease Diagnostic Solutions to the Global Diagnostics Industry

Share

H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary of Fujirebio Europe NV.

By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. We are excited to work together with the ADx NeuroSciences team to expand the global neurodegeneration biomarker testing market.”

“It is a unique opportunity for us to completely integrate the CDMO-based open platform strategy of Fujirebio in this way,” statesKoen Dewaele, CEO of ADx NeuroSciences. “Ourpartners will benefit from the synergies between our teams and the speed with which we can bring our antibodies and assays to the diagnostics industry and on various platforms, all under the high-quality mark of excellence for which Fujirebio has become well known.”

ADx NeuroSciences specializes in generating tailor-made antibodies and developing assays for pharma and in vitro diagnostics (IVD) companies. As part of Fujirebio, ADx NeuroSciences will continue to serve its current partners and customers in their diagnostic biomarker development and will continue to expand its extensive portfolio of state-of-the-art biomarkers and antibodies to help detect neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. Its current pipeline encompasses, next to several phospho-tau specific antibodies for measurement in plasma, biomarkers targeting synaptic degeneration supporting prognosis of these devastating diseases.

Fujirebio is a trusted partner for high-quality IVD testing solutions and a historical pioneer in neurodegenerative disease diagnostics. The company will combine the unique know-how and biomarker portfolio of ADx NeuroSciences with both its own solid experience in bringing high quality IVD products to the market and its strategic CDMO partnerships that make unique testing solutions available to the entire diagnostics industry. The acquisition also concentrates considerable additional know-how, expertise, and resources in the Fujirebio Neuro Center of Excellence.

About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., whose name represents “Healthcare for you” and which is a listed company on Tokyo Stock Exchange (TSE: 4544), is a global leader in the field of high-quality IVD testing. Founded in 1950, it has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products. With Fujirebio Holdings Inc., located in Tokyo, Japan, its subsidiaries are located in Japan, US and Europe.

Fujirebio was the first company to develop and market CSF biomarkers for Alzheimer’s disease testing, under the Innogenetics brand, over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier, and more complete neurodegenerative diagnostic tools.

About ADx NeuroSciences
ADx NeuroSciences is an R&D driven company specialized in the development of neurodegenerative biomarkers. Its expertise is used by pharmaceutical and diagnostic companies for the conception, development, production, and worldwide commercialization of novel biomarkers.

ADx NeuroSciences was founded in 2011 and is now working with the top pharmaceutical and diagnostic companies in US, Europe, Japan, and China. These collaborations result in new diagnostic assays that support the development of promising drugs either by monitoring the drug effect or by selecting the right patients at a very early stage of the disease. These assays are used in neurodegenerative diseases like Alzheimer’s disease and Parkinson’s and can be applied to a variety of platforms for research up to IVD use.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media:
Public Relations Section, Public Relations/Sustainability Department,

H.U. Group Holdings, Inc..
Phone: +81-3-6279-0884 
E-mail: pr@hugp.com

Christiaan De Wilde
CEO Fujirebio Europe
Phone: +32 9329 1703

For investors and analysts: 
IR/SR Dept.
Phone: +81-3-5909-3337 
E-mail:ir@hugp.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Travelex Bank Selects ThetaRay for Transaction Monitoring and Sanctions Screening6.7.2022 14:00:00 CEST | Press release

ThetaRay, a leading provider of AI-powered transaction monitoring technology, today announced that Travelex Bank, Brazil’s largest foreign exchange specialist, will implement ThetaRay’s SONAR anti-money laundering (AML) SaaS solution for both domestic and international transaction monitoring, as well as real-time sanctions screening for its international payments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005020/en/ Travelex Exchange Service (Photo: Business Wire) Travelex Bank is one of the world’s leading specialist providers of foreign exchange, offering a range of international money transfer products including import/export, remittances and mass payments. SONAR will empower Travelex Bank to detect attempts to launder money or circumvent financial sanctions through its system, bringing trust and confidence to all parties in the global payments ecosystem. Additionally, SONAR will allow the company to roll out n

BigCommerce utvider det globale avtrykket til Danmark, Norge, Sverige og Østerrike for å gi selgere mulighet til å skalere og få nettbutikkene sine til å vokse6.7.2022 14:00:00 CEST | Pressemelding

BigCommerce (Nasdaq: BIGC), en ledende åpen SaaS netthandelsplattform for raskt voksende og etablerte B2C- og B2B-varemerker, kunngjorde i dag at de har utvidet deres europeiske tilstedeværelse til Østerrike, Danmark, Norge og Sverige. Med sin DACH og nordiske ekspansjon og fullt lokaliserte teknologi- og byråpartner-økosystem, vil BigCommerce gjøre det mulig for selgere i alle størrelser og kompleksiteter å bygge og skalere nettbedriftene sine for å gi sømløse handleopplevelser til lokale og internasjonale kunder og øke inntektene. "BigCommerces nye tilstedeværelse i DACH og nordiske markeder gir en lokalisert, kraftig og skalerbar åpen SaaS netthandelsplattform til selgere i disse regionene som ikke tidligere har blitt tilbudt disse kjerneprinsippene i én løsning," sa Jim Herbert, senior visepresident og daglig leder EMEA hos BigCommerce. «Med vår velprøvde netthandelsplattform i enterprise-grad, vil selgere av alle typer ha de gode verktøyene og innovative funksjonalitetene – fra he

KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland6.7.2022 13:45:00 CEST | Press release

KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/ KBI Biopharma and Selexis ribbon cutting at their new state-of-the-art facility in Geneva, Switzerland, Tuesday, July 5, 2022 (from left to right: Mark Lutgen, KBI Biopharma, VP of Global Engineering; Mario Rodriguez, Mayor, Plan-les-Ouates; Fabienne Fischer, State Councilor and Head of the Department of the Economy and Employment; Ma

ADVA Optical Networking SE: Approval of public exchange offer of Acorn HoldCo, Inc. by German Federal Ministry of Economics and Climate Protection6.7.2022 12:45:00 CEST | Press release

Today, the German Federal Ministry for Economics and Climate Protection (“BMWK”) has granted the foreign direct investment approval that was required for closing the public exchange offer made by ADTRAN Inc.’s subsidiary, Acorn HoldCo, Inc. (“Acorn HoldCo”). With the foreign direct investment approval by the BMWK, all offer conditions for Acorn HoldCo’s public exchange offer published on 12 November 2021 are fulfilled. The settlement of the exchange offer is expected by 15 July 2022, but at the latest on 18 July 2022. Acorn HoldCo’s shares will be admitted to trading on NASDAQ and the Frankfurt Stock Exchange. Disclaimer To the extent any announcements in this document contain forward-looking statements, such statements do not represent facts and are characterized by the words "will", "expect", "believe", "estimate", "intend", "aim", "assume" or similar expressions. Such statements express the intentions, opinions or current expectations and assumptions of ADVA and the persons acting j

GlobalLogic Achieves Green Sustainability Ranking via the NQC SupplierAssurance Platform6.7.2022 12:00:00 CEST | Press release

GlobalLogic Inc., a Hitachi Group company and a leader in Digital Engineering, today announced it has achieved a Green rating via the NQC SupplierAssurance platform—a cloud-based solution used by suppliers to determine their sustainability performance level. Based on the Self-Assessment Questionnaire (SAQ 4.0) and validated by the NQC Supplier Assurance Team for accuracy, the results show GlobalLogic earning a score of 72% in its market category of Engineering and Research Technology Based Services. That score is significantly higher than the category average of 47% across more than 1200 locations. The automotive industry in particular has increased its focus on green initiatives. Stringent regulations and standards requiring substantial improvements to automotive manufacturing practices and direct environmental impact have been implemented in various regions. Examples range from the European Commission’s EU 2019/631 regulation targeting vehicle CO2 emissions to numerous ISO standards